Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test
Portfolio Pulse from
Lucid Diagnostics has secured its first positive commercial insurance coverage policy for its EsoGuard® Esophageal DNA Test from Highmark Blue Cross Blue Shield in New York. This policy covers non-invasive screening for esophageal precancer and cancer.
March 13, 2025 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lucid Diagnostics has achieved a significant milestone by securing its first commercial insurance coverage for the EsoGuard® test, potentially increasing its market reach and revenue.
The insurance coverage by Highmark Blue Cross Blue Shield is a major step for Lucid Diagnostics, as it allows for broader adoption of their EsoGuard® test. This could lead to increased sales and revenue, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
PAVmed Inc., the parent company of Lucid Diagnostics, may benefit from the insurance coverage of the EsoGuard® test, potentially enhancing its financial performance.
As the parent company of Lucid Diagnostics, PAVmed Inc. stands to benefit from the increased market penetration and potential revenue growth resulting from the insurance coverage of the EsoGuard® test.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70